FIELD: medicine.
SUBSTANCE: invention relates to a novel compound of formula I or a pharmaceutically acceptable salt thereof having a selective impact on PDE1. In formula I
X represents -CH- or -N-; Y - O- or -S-; M is 0-3; each of R1 is independently selected from the group consisting of: H, halogen, -C1-6alkyl, -C1-6haloalkyl, -C1-6alkoxy, -C1-6haloalkoxy, and phenyl; each of R3 and R4 is independently selected from the group consisting of: -H; halogen; -C1-6alkyl; -C1-6haloalkyl; -CH2OH; -C1-6alkoxy; -C1-6haloalkoxy; optionally substituted 5- or 7-membered heteroaryl having 1-3 heteroatoms selected from: N, O, or S, in which the substituents are independently selected from C1-C6alkyl, HOCH2, halogen, -CH2N(C1-C4alkyl)-C(=O)-, N(C1-C4alkyl)2, -CH2N(C1-C4alkyl)2, benzyl, -CH2-5-7-membered monoheterocycloalkyl having 1 to 2 heteroatoms selected from N, O, optionally substituted C1-C4alkyl, oxo, C1-C4alkylsulfonyl, or -CH2-5-6-membered monoheterocycloalkyl having a nitrogen atom in the ring condensed with a benzene ring, or -CH2-7-9-membered bicyclic heterocycloalkyl having 1 to 2 heteroatoms selected from N or O; -(C1-C6alkyl)phenyl; -(C1-C6alkyl)-5-6-membered heteroaryl having 1 to 2 heteroatoms selected from N and O, and -(CR10R11)1-3NR12R13; or R3 and R4, taken together with the carbon atoms to which they are attached, form a saturated or unsaturated monocyclic ring system having the following structure:
where D is a bond, or -O-, or -N(R9)-, where R9 represents -H, -C1-6alkyl, -halogen-C1-6alkyl, -C1-6alkylthiomethyl, -C1-6alkyl-SO2methyl, -C1-6alkoxyC1-6alkyl, -halogen1-6alkoxyalkyl, -C1-6alkylphenyl, -C1-6alkyl (C3-6cycloalkyl), -C1-6alkyl (4-6-membered saturated heterocycloalkyl with 1-2 heteroatoms, selected from N and O), -C1-6alkyl(phenyl, optionally condensed with 5-6 membered saturated heterocycloalkyl with 1-2 heteroatoms, selected from O), C1-6alkyl (5-6 membered heteroaryl with 1 to 3 heteroatoms selected from N, S or -SO2) or 4-6 membered heterocycloalkyl with heteroatoms selected from O, S, wherein each of said substituents is optionally substituted with -Cl, -F or -CH3; each of m and n is independently 0-3 upon condition that the sum of m and n is 1-3, when D is -O-, -N(R9) -, or is 2-3 when D represents a bond; and with the proviso that when D is a bond, R1 does not represent -Cl in the para position; each of R5, R6, R7, R8 is independently selected from the group consisting of: -H, -C1-6alkyl, -C1-6haloalkyl, -OH, -C1-6alkoxy, -C1-6haloalkoxy; each of R10 and R11 is independently selected from the group consisting of: -H, -C1-6alkyl, -hydroxyC1-6alkyl, -C1-6alkoxyC1-6alkyl, CH2OH, -OH, -COCH3, and -SO2CH3; each of R12 and R13 is independently selected from the group consisting of: -H, -C1-6alkyl, -C3-6cycloalkyl, -C1-6alkyl(phenyl), -C1-6alkyl (5-6 membered heteroaryl with 1-2 heteroatoms selected from N and O), and -CH2CON (C1-6alkyl)2; or R12 and R13, taken together with the nitrogen atom to which they are attached form a 5-7 membered mono- or 7-9 membered bicyclic heterocycloalkyl ring with 1-2 heteroatoms selected from N and O, optionally substituted with one or two R14, where each R14 is independently selected from the group consisting of -H and -C1-6alkyl.
EFFECT: compounds can be used in the treatment of a disease or disorder selected from the group comprising a variety of diseases and disorders, including cognitive deficits associated with diseases and disorders of the central nervous system, neurological disorders, cardiovascular disorders, renal disorders, hematologic disorders, disorders of the gastrointestinal tract and liver, cancerous disorders and neurodegenerative disorders.
56 cl, 1 tbl, 224 ex
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED COMPOUNDS OF PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE | 2013 |
|
RU2653054C2 |
SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-7-YL COMPOUNDS AS THE INHIBITORS OF PDE2 | 2015 |
|
RU2659070C9 |
COMPOUNDS OF FORMULA (I) AND FORMULA (A), PHARMACEUTICAL COMPOSITION, MEDICINAL PRODUCT, USE AND METHOD OF OBTAINING COMPOUNDS OF FORMULA (I) | 2018 |
|
RU2822758C2 |
USE OF 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | 2017 |
|
RU2759380C2 |
TRICYCLIC NITROGEN-CONTAINING DERIVATIVES OF IMIDAZO[4,5-C]PYRIDINE, HAVING INHIBITING ACTIVITY IN RESPONSE TO HYSTAMINE 4 RECEPTOR (HH4R) | 2012 |
|
RU2628074C2 |
BENZOXAZEPINE PI3 INHIBITORS AND METHODS OF USE | 2010 |
|
RU2654068C1 |
BENZOXAZEPINE PI3K INHIBITORS AND METHODS OF USE | 2010 |
|
RU2600927C2 |
BENZOXEPIN PI3 INHIBITORS AND METHODS FOR USING THEM | 2010 |
|
RU2557658C2 |
DIAMINOTRIAZOLES, SUITABLE AS INHIBITORS OF PROTEIN KINASES | 2003 |
|
RU2350606C2 |
4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | 2020 |
|
RU2822388C2 |
Authors
Dates
2018-07-04—Published
2013-06-18—Filed